INTRODUCTION
Human bronchial mucins consist of a family of polydisperse glycoproteins of high molecular weight, with different polypeptide chains (named apomucins) substituted by carbohydrate chains in serine and threonine rich tandem repeats that are responsible for about 70 to 80 % of their apparent molecular weight [1] . Apomucins of bronchial mucins are encoded by at least eight mucin (MUC) genes (MUC1, MUC2, MUC4, MUC5B, MUC5AC, MUC7, MUC8, and the recently characterized MUC19) [2] . Carbohydrate chains that cover the apomucins are extremely diverse, adding to the complexity of these molecules. Currently, more than 150 different O-linked carbohydrate chains have been described, and it is assumed that the bronchial mucins from a single individual probably contain a few hundred different carbohydrate chains [3] . In addition, because bronchial mucins are located at the surface of airways, where they have a protective function, the broad diversity of their carbohydrate peripheral determinants could be involved in multiple interactions with bacteria and viruses, which are then normally eliminated by the mucociliary system. O-sulfotransferases (GAL3ST), and (iv) N-acetylglucosamine-6-O-sulfotransferases (CHST) [4] . In the lung, it is not very clear yet which fucosyl-, sialyl-, and sulfotransferases are involved in the biosynthesis of these determinants that are present at the periphery of mucins and probably crucial in many pathologies, including cystic fibrosis.
Inflammation plays a major role in the pathophysiology of lung disease in cystic fibrosis (CF 1 ): the inflammatory response is thought to be abnormal and/or excessive in cystic fibrosis, which would contribute to the degradation of the respiratory function of the patients. It is still a matter of debate whether there may or may not be a pre-inflammation of the lungs as part of the basic functional defect of the cystic fibrosis transmembrane conductance regulator (CFTR). Armstrong and colleagues [5] have suggested that inflammation may even precede infection in this disease. The presence of increased neutrophils and cytokines such as tumour necrosis factor (TNF , interleukins (IL) -6 and -8 in young infants with cystic fibrosis with no evidence of infection has also been shown [6] [7] . There is also accumulating evidence that the secretion of several cytokines, especially IL-8, is up-regulated in CF [8] . In contrast, bronchoalveolar lavages from cystic fibrosis patients contain less antiinflammatory cytokine IL-10 than healthy controls and bronchial epithelial CF cells secrete less IL-10 than normal cells, suggesting that there could be an imbalance between pro-and anti-inflammatory cytokines in cystic fibrosis, leading to an exaggerated inflammatory response that would be at the onset of the lung disease and/or would contribute to the lung disease development [9] [10] .
Glycosylation defects on glycoconjugates secreted by CF patients or present on the membrane of CF cells have been described since the 70's. Bronchial mucins secreted by CF patients are more sulfated, sialylated and fucosylated, and salivary and intestinal mucins from CF patients also contain more sulfate than healthy individuals [11] [12] [13] . In addition, it has been shown the sialyl-Lewis x epitope is overexpressed on bronchial mucins from severely infected CF patients, but also on bronchial mucins from infected patients suffering from other lung pathologies [14] . patients, which confirmed the increased presence of sialyl-Lewis x epitopes and HO 3 S-6-Nacetylglucosamine (GlcNAc) residues [15] .
Interestingly, it seems that glycosylation of secreted and membrane glycoconjugates is either not affected by the level of expression of CFTR [16] [17] or that membrane bound CF glycoconjugates are differently affected than secreted glycoconjugates. CF membrane glycoconjugates show a decreased sialylation compared with non-CF [18] whereas mucins secreted by CF patients are oversialylated.
These discrepancies suggest that other factors than the CFTR deficiency could be responsible for the altered glycosylation and sulfation of CF mucins. It is of particular interest to understand the origin of the sialylation, fucosylation and sulfation modifications carried by CF bronchial mucins, because the sialyl-Lewis x and 6-sulfo-sialyl-Lewis x epitopes that are overexpressed on these mucins are preferential receptors for P. aeruginosa, the bacteria responsible for the progressive destruction of CF patients lungs [19] . As already mentioned, it has been shown that inflammation could induce modifications of glycosylation in the lung, such as an overexpression of the sialyl-Lewis x epitope on bronchial mucins [14] . In addition, the pro-inflammatory cytokine TNF can induce increased expression and activities of some sialyl-, fucosyl-, and sulfotransferases in human bronchial explants as well as in the human respiratory glandular cell line (MM-39) [20] . IL-6 and IL-8 are present in high amount in bronchoalveolar fluids from CF, but their effect on glycosylation is still unknown.
In the present study, we have investigated the effect of these two cytokines on the expression and activity of bronchial glycosyl-and sulfotransferases. We show an increased expression of several fucosyl-, sialyl-and sulfotransferases, as well as increased amounts of sialyl-Lewis x and 6-sulfo-sialylLewis x epitopes on bronchial proteins, including MUC4, which could influence the development of the lung pathology.
EXPERIMENTAL Materials
The monoclonal antibodies (mAb) against the sialyl-Lewis x (CSLEX1)and 6-sulfo-sialyl-Lewis 
Explants Culture
In accordance with the Declaration of Helsinki (2000) of the World Medical Association, after ethical committee approval (CHRU Lille) and informed consent from patients had been obtained, tissues were collected in macroscopically healthy areas of the bronchial tree from patients undergoing surgery for bronchial carcinoma. They were immersed in Leibovitz L15 medium (Invitrogen), immediately transported on ice to the laboratory, and then processed to isolate the mucosa. Mucosa (1-2 cm 2 )
were cut into 1-mm 2 pieces and suspended in CMRL-1066 medium (Invitrogen) complemented with 0.2 mM L-glutamine [4] . They were maintained at 37°C for 16 h in the presence or absence (controls) of 20 ng/ml IL-6 or IL-8 (AbCys S.A., France).
RNA Isolation and cDNA Synthesis
Total RNA was isolated from fragments of bronchial mucosa incubated with and without IL-6 or IL-8 for 16 h, using the NucleoSpin ® RNA II (Macherey-Nagel). Isolated RNA (1-2 g) was then subjected to reverse transcription in the presence of oligodeoxythymidilic acid [12] [13] [14] [15] [16] [17] [18] primer (First strand cDNA synthesis kit, Amersham Biosciences) for cDNA synthesis in a final volume of 33 l according to the manufacturer's instructions.
Semi-quantitative and quantitative PCR Analysis of Mucin, Glycosyltransferase and Sulfotransferase Transcriptional Expression
The oligonucleotides used as primers for the PCR reactions are given in Tables I and II ( were from a previous study, the amplification conditions were according to the author's instructions (see Tables 1 and 2 for references). For primers designed for this study, the amplification conditions were the following: 95°C for 2 min, 1 cycle; 95°C for 1 min, Ta (Annealing temperature, see Table I) for 1 min, 72°C for 1 min, 39 cycles, 72°C for 5 min, 1 cycle. Twenty microliters of the PCR reaction were submitted to electrophoresis on an agarose gel (2% in a Tris Borate EDTA buffer) containing ethidium bromide. Gels were photographed under UV light, and the expression of the different enzymes was analyzed. This first step allowed us to select the genes expressed in control or treated human bronchial explants.
Variations in the enzyme mRNA levels present in control or treated bronchial explants were then quantified by real-time PCR. Real-time PCR and subsequent data analysis were performed using the Tables 1 and 2) 
Statistical Analysis
Variations in mRNA levels of glycosyltransferases were calculated on 6 individual mucosae treated or not with IL-6 or IL-8 (20 ng/ml, 16 h). The Student's t test was used to compare the means of the relative amount of each glycosyl-or sulfotransferase between the groups of treated and control explants.
Statistical significance for this analysis was considered at p < 0.05.
Preparation of total proteins from bronchial explants
After 16 h incubation in CMRL-1066 +/-20 ng/ml of IL-6 or IL-8, pieces of mucosa were collected and centrifuged at 10 000 x g for 5 min at 4 °C, and then rinsed two times with ice cold phosphate buffer saline (PBS). Pieces of mucosa were then disintegrated on ice with a glass homogenizer, in a modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, containing 1 mM ethylenediaminetetracetic acid, 1 mM phenylmethylsulfonylfluoride, 1 % Triton X-100, 1 % sodium deoxycholic acid, and a cocktail of protease inhibitors (Roche)). Protein extracts were then centrifuged Amersham Biosciences, Little Chalfont, United Kingdom). MUC4 mucin detection in explants was carried out as previously described using a 1µg/ml dilution of the antibody m8G7 [22] .
Lectin blotting analysis
Sample preparation and electrophoresis were conducted as described above. After transfer on nitrocellulose membrane (250 mA, 5h), blocking was performed in TBS containing 2 % polyvinylpyrrolidone for 90 min, followed by incubation with alkaline phosphatase conjugated MAA or alkaline phosphatase conjugated SNA, lectins that recognizes preferentially 2,3-linked or 2,6-linked sialic acid residues, respectively (dilution 1:75 in TBS containing 1 mM MgCl 2 , 1 mM MnCl 2 , 1 mM CaCl 2 , pH Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
topes in CF patients, total proteins extracted from bronchial explants, treated or not with IL-6 or IL-8
were analyzed by Western blotting. Samples from bronchial mucosa from 5 independent individuals were used to test the effect of both cytokines. 2,3-and 2,6-sialylation were analyzed using MAA and SNA lectins, respectively, and sialyl-Lewis x and 6-sulfo-sialyl-Lewis x by immunoblotting using specific mAbs. Staining with MAA and SNA, lectins that recognize preferentially 2,3-or 2,6-linked sialic acid residues, respectively, was not modified in bronchial samples treated with either IL- These data suggest that IL-6 or IL-8 did not deeply modified the overall sialylation pattern of bronchial mucosa but only increased the expression of specific glycan motifs, such as sialyl-Lewis x and 6-sulfo-sialyl-Lewis x .
Identification of proteins carrying the 6-sulfo-sialyl-Lewis x epitope
Immunoblotting experiments suggest that proteins that carry sialyl-Lewis x and 6-sulfo-sialyl-Lewis x epitopes in bronchial explants could correspond to mucins, because of their high apparent molecular weight and diffuse migration pattern. In order to test this hypothesis, we quantatively determined using real-time PCR the level of mucin gene expression in the bronchial mucosa and checked whether their expression was modified by cytokine treatment. In all samples, MUC4 was more expressed than MUC5B, which was more expressed than MUC5AC in most of the patients (Figure 3) . MUC6 was expressed at very low levels (Ct > 35) in bronchial explants and therefore could not be accurately quan- Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
were observed in control conditions and the effect of IL-6 and IL-8 was extremely variable between samples, with sometimes a stimulatory effect, or an inhibitory effect, or no effect at all (data not shown). These results indicate that the increase in sialyl-Lewis x and 6-sulfo-sialyl-Lewis x epitopes can not be directly linked to increased expression of mucin genes. The presence of mucins in the bronchial samples was also analyzed in total protein extracts from bronchial explants. Immunoblotting experiments showed a high expression of MUC4 in bronchial protein extracts. MUC1 and MUC5B were also detected but at a lower level compared to MUC4, and MUC5AC was not detected, confirming the results of real-time PCR analysis (data not shown, and Fig. 3) . Moreover, the band of high molecular weight visualized using the 6-sulfo-sialyl-Lewis x antibody was in most cases also stained with the anti-MUC4 antibody (Figure 4 ), but not with anti-MUC5B or anti-MUC1 mAbs (data not shown),
suggesting that MUC4 is the main protein carrying 6-sulfo-sialyl-Lewis x epitopes in the human bronchial mucosa.
Effect of IL-6 and IL-8 on the transcriptional expression of sialyl-, fucosyl-and sulfotransferases from bronchial explants.
In order to determine which enzymes are responsible for the increased amounts of sialyl-Lewis treatment, whereas the expression of FUT11 (encoding a potential fucosyltransferase of still unknown specificity) was moderately but significantly increased in the different explants tested ( Figure 5A and B). GAL3ST2 and GAL3ST3 genes encoding Gal-3-O-sulfotransferases were not expressed at quantifiable levels in the bronchial explants, and the expression of GAL3ST4 was not significantly affected by the addition of IL-6 or IL-8 ( Figure 5 ). Among the GlcNAc-6-O-sulfotransferase encoding genes, only CHST4 and CHST6 were expressed in our model, with CHST6 in average expressed 2.8-fold more than CHST4. Both enzymes had their expression increased under IL-6 treatment, whereas IL-8 had only a significant stimulatory effect on CHST6 expression ( Figure 5 ). Altogether, these results identify the glycosyl-and sulfotransferases that could be involved in the increased expression of sialyl-Lewis x and 6-sulfo-sialyl-Lewis x epitopes in the bronchial mucins in inflammatory mucosae of CF patients ( Figure 6 ).
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DISCUSSION
Our study clearly demonstrates the influence of IL-6 and IL-8, two pro-inflammatory cytokines, on the expression and activity of several fucosyl-, sialyl-and sulfotransferases involved in the biosynthesis of sialyl-Le x and 6-sulfo-sialyl-Le x epitopes by the human bronchial mucosa. Several independent studies have previously shown that IL-6 and to a lower extent IL-8 can modulate protein secretion and glycosylation [23] [24] . IL-6 also modulates the expression of some mucin genes by inducing an early response of MUC2, MUC5B and MUC6 mucin genes in LS180 cells [25] . In parallel, IL-8 is a chemokine that attracts neutrophils to the inflammatory sites and seems constitutively up-regulated in CF cells [26] . Its effect on glycosylation is not well documented but IL-8 has been shown to stimulate the expression of MUC5AC and MUC5B genes [27] . Considering that these two cytokines are key actors in the chronic and destructive inflammatory response exhibited by the lung of CF patients, it is therefore of particular interest to investigate the effect of these two pro-inflammatory cytokines on glycosylation process in human bronchial cells.
Our results show that the increase of sialyl-Le x and 6-sulfo-sialyl-Le x in cytokine treated explants is specific of a very limited number of high molecular weight proteins whereas staining with MAA or SNA reveals a broad population of 2,3-and 2,6-sialylated glycoproteins unaffected by cytokine treatment. These results is in agreement with those of Davril et al. (1999) [14] who have shown that the amount of sialyl-Le x epitopes on high molecular weight bronchial glycoproteins depends on the severity of airway infection / inflammation and on the nature of the bacteria present in the sputum.
The influence of inflammation on the biosynthesis of 6-sulfo-sialyl-Le x epitope has not been studied before, and it is the first time that a stimulatory effect of pro-inflammatory cytokines on that biosynthetic pathway is shown. The anti-6-sulfo-sialyl-Le x labelling showed a broad band of high molecular weight, and the immunostaining with anti-MUC mAbs strongly suggests that this epitope is carried by the membrane-bound MUC4.
Variations in the levels of expression of MUC genes were observed between the bronchial samples, which is not surprising considering the different factors inducing heterogeneity in the model of human bronchial explants. Indeed, explants were obtained from patients differing in age, sex, stage of the disease and treatment before surgery, and the lung area from which the explant was obtained can also vary. It is known that the gel-forming mucin genes (MUC2, -5AC, -5B, -6) are regulated at the transcriptional level by pro-inflammatory cytokines such as IL-1 , TNF and IL-6, pleiotropic cytokines (IL-4, IL-13, IL-9), as well as by other mediators like growth factors and hormones [25, [28] [29] In this study, the effect of IL-6 and IL-8 on MUC4, -5AC, and 5B expression was investigated, but inconsistent effects of both cytokines on the expression of these genes was observed, with sometimes opposite effects from one sample to the other. This seems to indicate that the effect of cytokines on MUC gene expression observed with cultured cells is not directly transposable to bronchial explants.
As it has already been reported by Delmotte and co-workers, no expression of fucosyltransferases genes FUT1, FUT5, FUT6, and FUT7 was observed in bronchial explants [20] . In addition, we found that FUT9 gene encoding an enzyme preferentially synthesizing the Le x epitope [30] , is not expressed in the control or treated bronchial explants and FUT4, encoding a fucosyltransferase that preferentially synthesizes the sialyl-Le x epitope [31] , was only detectable in a few samples. Interestingly,
FUT10
and FUT11 genes encoding putative 1,3/4-fucosyltransferases of still unknown activities [32] , are expressed in human bronchial mucosa. As already described, human bronchial explants express FUT2, encoding the secretor enzyme, and FUT3, encoding the Lewis enzyme [20] . The two 2,6-sialyltransferase genes ST6GAL1 and ST6GAL2 are expressed in human bronchial explants and respond in a different way to the addition of cytokines. The expression of ST6GAL1 was not affected by the addition of IL-6 or IL-8, whereas ST6GAL2 was strongly induced by both cytokines in all treated explants. ST6Gal I expression was previously shown to be IL-6 dependent in hepatocytes. In liver, ST6GAL1 is expressed as a 4.3 kb transcript under the control of a liver-specific promoter different from the promoter used in other tissues, in which ST6GAL1 is expressed as a 4.7 kb transcript [35] . This tissue-specific expression of ST6GAL1 could explain the absence of induction in cytokine treated explants. Whereas ST6GAL2 was strongly induced in all cytokine treated explants, SNA labelling shows that 2,6-sialylation of glycoproteins is not modified in treated bronchial explants. This result could be explained by the differences in substrate specificity and expression levels of these two enzymes: ST6Gal I is an ubiquitously expressed enzyme involved in the 2,6-sialylation of glycans carrying type 2 disaccharide units (Gal 1-4GlcNAc). ST6Gal II shows a much more restricted expression pattern and exhibits a slightly different substrate specificity [36] [37] , acting preferentially on LacdiNAc structures (GalNAc 1-4GlcNAc), a motif present on very few human glycoproteins. It is likely that the 2,6-linked sialic acids present in explants (and visualized by SNA staining)
are carried by the classical type 2 disaccharides present mostly on N-glycan branches, which are a better substrate for ST6Gal I. In addition, although not induced by cytokines, the level of expression of ST6GAL1 is higher than ST6GAL2 (even in treated explants). Until now, sialyl-LacdiNAc has never been characterized in human bronchial tissue but its limited expression onto specific glycoproteins could occur and play a specific role during inflammation.
Among 2,3-sialyltransferases genes (ST3GAL3, 4 and 6) involved in the sialylation of type 2 units (the precursor of the sialyl-Le x epitope), only ST3GAL6 expression was significantly increased in IL-6 treated bronchial explants. This enzyme was already shown to be expressed in human and mouse lung [33, 38] and is therefore a good candidate for the synthesis of the sialyl-Le x epitope in this tissue.
ST3GAL3 and ST3GAL4 are both expressed in our model but their expression was not significantly affected by IL-6 or IL-8.
Human bronchial mucins were shown to contain sulfate residues, either on the C3 of terminal Gal residues, or on the C6 of internal GlcNAc residues [15] . In cystic fibrosis, bronchial mucins are highly sulfated, and the structures determined by [ 1 H]-NMR and MS suggest that CF bronchial mucins carry more sulfated GlcNAc residues than mucins from patients suffering from chronic bronchitis. Genes encoding Gal-3-O-sulfotransferases active on glycoproteins showed either very low or no expression in our model, except GAL3ST4. The sulfotransferase Gal3ST4 was previously shown to be active on mucin-type structures [39] . Although Delmotte and co-workers could detect an increased Gal-3-O- Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
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sulfotransferase activity in TNF -treated bronchial explants [20] , the addition of IL-6 or IL-8 did not significantly modify the expression of ST3GAL4 in a similar model.
Among genes encoding GlcNAc-6-O-sulfotransferases, we studied CHST2 and CHST4, two genes encoding enzymes able to synthesize the 6-sulfo-sialyl-Le x epitope, especially on HEV. CHST2 was not expressed in bronchial explants, whereas the expression of CHST4 was slightly increased in the presence of IL-6. The expression of CHST4 was previously shown to be induced by TNF-in cultured endothelial cells [40] . It is of interest that both allergic sheep and human asthmatics exhibit airway secretions, presumably mucins that are stained by the monoclonal antibody MECA-79 [41] . MECA-79
recognizes mucin-type core-1 extended with a 6-sulfo-sialyl-Le x determinant. It seems that the major source of MECA-79-reactive glycoproteins is the airway epithelium in which CHST4 was found to be expressed. It has been proposed that the MECA-79 reactive secretions could provide extravascular ligands (adhesive or signalling) for leukocytes migrating into airways [41] .
We also investigated variations in the expression of genes encoding sulfotransferases acting on glycoproteins but not preferentially involved in 6-sulfo-sialyl-Le x biosynthesis, i.e. the gene encoding GlcNAc6ST-3 [42] , and CHST6 [43] that acts preferentially on terminal GlcNAc residues of keratan sulfate chains. Enzymes encoded by these two genes have not been yet implicated in 6-sulfo-sialylLe x biosynthesis, but they both sulfate terminal GlcNAc residues of oligosaccharide chains and are therefore potential candidates for this biosynthesis pathway. The gene encoding GlcNAc6ST3 was not expressed in both control or treated bronchial explants. CHST6 expression was induced both by IL-6
and IL-8 in the bronchial explants, although moderately concerning IL-8. Our results point at CHST4
and CHST6 as major sulfotransferase genes expressed and induced by cytokines in bronchial explants.
Altogether, this study allows us to suggest which enzymes are involved in the cytokine-induced sialylLe x and 6-sulfo-sialyl-Le x biosynthesis in the bronchial mucosa of CF patients ( Figure 6 ).
Sialyl-Le x epitopes have been detected on mucin-type glycoproteins in different cell types and display important biological roles. Cell surface sialyl-Le x is recognized by the endothelial selectins, is involved in leukocyte homing and rolling during inflammation [44] . Sialyl-Le x is also overexpressed in many carcinomas and is usually considered as a poor prognosis factor, since the interaction of this epitope with selectins facilitates extravasation and spreading of cancer cells [45] . Interactions between macromolecules carrying abnormally expressed Sialyl-Le x and cells carrying selectins (leucocytes, endothelial cells) could modulate the inflammatory response, by competing with the relevant selectin ligands [46] . 6-sulfo-sialyl-Le x is a major sulfated L-selectin ligand present on mucin-type proteins such as CD34 and GlyCAM-1 on high endothelial venules (HEV) of lymph nodes and is essential for lymphocyte rolling and lymphocyte recruitment [47] . Our results suggest that in airway mucosa, the inflammation-induced 6-sulfo-sialyl-Le x determinant is carried by the membrane-bound bronchial mucin MUC4. Interestingly, MUC4 overexpression is a poor prognosis factor in pancreas and lung cancers, and MUC4 has been shown to be involved in pancreatic cancer progression, by modifying interactions between cancer cells and the extracellular matrix [48] . Importantly, MUC4 expression is Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
negatively regulated by CFTR, the protein deficient in CF patients [49] . In the bronchial mucosa of severely infected CF patients, one could therefore expect increased levels of abnormally glycosylated MUC4 that could affect signalling and interactions. The increased expression of sialyl-Le x and 6-sulfo-sialyl-Le x after cytokine treatment in human bronchial explants is therefore of important biological relevance and offers an increased number of potential ligands for leukocytes and for the binding of P. aeruginosa, and may therefore contribute to the chronicity of airway infection in cystic fibrosis. Moreover, the interactions of P. aeruginosa with mucins may prevent its opsonophagocytic killing by human polymorpho-nuclear cells [50] .
Here we show which glycosyl-and sulfotransferases are up-regulated by IL-6 and IL-8 in the human bronchial mucosa, resulting in increased amounts of sialyl-Le x and 6-sulfo-sialyl-Le x epitopes on bronchial proteins, which are key determinants in the development and chronicity of the lung inflammation and infection. In the future, the study of the mechanisms by which these enzymes are regu- Total proteins from control or stimulated explants were resolved by SDS-PAGE using 3-10 % gels, transferred on nitrocellulose. 2,3-linked and 2,6-linked sialic acids were detected by MAA and SNA, respectively. Total proteins from control or stimulated explants were resolved by SDS-PAGE using 3-10 % gels, transferred on nitrocellulose, and sialyl-Lewis x and 6-sulfo-sialyl-Lewis x were detected using antisialyl-Lewis x CSLEX1 (A) and anti-6-sulfo-sialyl-Lewis x G152 mAbs (B), respectively. Total proteins from control or stimulated explants were resolved by SDS-PAGE using 3-10 % gels. 6-sulfo-sialyl-Lewis x and MUC4 were detected using anti-sialyl-Lewis x G152 or anti-MUC4 m8G7 mAbs, respectively. Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
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